Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2012

View Archived Issues

Tenascin-C evaluated as a marker of isolated noncompaction cardiomyopathy

DNA decoy to prevent postsurgical pain shows promising preclinical toxicity profile

Preclinical data support clinical testing of new antiarrhythmic drug

Theravance product shows strong antinociceptive activity across a range of pain models

Jakavi approved in Europe

European Commission approves Zinforo

Novel agent is active against West Nile virus and other flaviviruses / News in Context

Bristol-Myers Squibb presents in vivo results on new Trk inhibitors

New potential cancer therapies developed at U.S. university

Genmab designs novel CD74-directed immunotherapies

Novel candidate HIV medicines presented by Bristol-Myers Squibb

Scientists in U.S. disclose novel HDAC inhibitors

Boehringer Ingelheim Pharma patents new PI3K-alpha inhibitors

New MDR efflux pump inhibitors synthesized in France

Esperance advances phase II trial in ovarian cancer

New assay to measure testosterone obtains CE mark

FDA committee to discuss Heplisav BLA

Biomarker has prognostic value in patients with diabetes and coronary artery disease

Cangene strengthens biodefense work

Resverlogix reports topline results from SUSTAIN study

Health Canada approves Treanda

Altheus Therapeutics kicks off phase II trial in ulcerative colitis

Novelos Therapeutics developing optical imaging agent for use in cancer

First patient enrolled in phase IIa AEZS-130 study

CE Mark approval for Elixir Medical stent

Pristine Solutions completes acquisition

Promising phase IIa data reported on Archexin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...